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The PHEX gene (phosphate-regulating gene with homologies
to endopeptidases on the X chromosome) encodes a protein
(PHEX) with structural homologies to members of the M13
family of zinc metallo-endopeptidases. Mutations in the PHEX
gene are responsible for X-linked hypophosphataemia in humans.
However, the mechanism by which loss of PHEX function
results in the disease phenotype, and the endogenous PHEX
substrate(s) remain unknown. In order to study PHEX substrate
specificity, combinatorial fluorescent-quenched peptide libraries
containing o-aminobenzoic acid (Abz) and 2,4-dinitrophenyl
(Dnp) as the donor–acceptor pair were synthesized and tested
as PHEX substrates. PHEX showed a strict requirement for
acidic amino acid residues (aspartate or glutamate) in S′1 subsite,
with a strong preference for aspartate. Subsites S′2, S1 and S2
exhibited less defined specificity requirements, but the presence
of leucine, proline or glycine in P′2, or valine, isoleucine or
histidine in P1 precluded hydrolysis of the substrate by the
enzyme. The peptide Abz-GFSDYK(Dnp)-OH, which contains
the most favourable residues in the P2 to P′2 positions, was
hydrolysed by PHEX at the N-terminus of aspartate with a kcat/Km
of 167 mM−1 · s−1. In addition, using quenched fluorescence
peptides derived from fibroblast growth factor-23 and matrix
extracellular phosphoglycoprotein sequences flanked by Abz
and N-(2,4-dinitrophenyl)ethylenediamine, we showed that these
physiologically relevant proteins are potential PHEX substrates.
Finally, our results clearly indicate that PHEX does not have
neprilysin-like substrate specificity.
Key words: combinatorial library, internally quenched fluorogenic
substrate, M13 endopeptidase, PHEX substrate specificity.
INTRODUCTION
PHEX (phosphate-regulating gene with homologies to endopep-
tidases on the X chromosome) was first identified by positional
cloning as the gene that is mutated in patients with X-linked
hypophosphataemia (XLH) [1]. XLH is the most prevalent
form of inherited rickets in humans and is characterized by
growth retardation, rachitic and osteomalacic bone disease,
hypophosphataemia and renal defects in phosphate reabsorption
and vitamin D metabolism [2]. Much of our knowledge about
XLH has been obtained from studies of the Hyp mouse, which
has a large deletion of the Phex gene [3] and has been used as an
animal model for the human disease [4].
The product of the PHEX gene (PHEX) shows striking homolo-
gies to members of the M13 family of zinc metallo-endopeptidase.
These enzymes are type-II integral membrane glycoproteins
[5] and include neprilysin (NEP; neutral endopeptidase 24.11)
[6], endothelin-converting enzymes (ECE-1 and ECE-2) [7],
Kell blood group protein [8], ECE-like enzyme/distress-induced
neuronal endopeptidase (‘ECEL1/DINE’) [9,10], soluble endo-
peptidase/NEP-like enzyme 1/neprilysin 2 (‘SEP/NL1/NEP2’)
[11–13] and membrane metallo-endopeptidase-like 2 (‘MMEL2’)
[14], although the latter might be the human homologue of
SEP/NL1/NEP2. The use of specific inhibitors has demonstrated
Abbreviations: Abz, o-aminobenzoic acid; ADHR, autosomal dominant hypophosphataemic rickets; DMP1, dentin matrix protein 1; Dnp, 2,4-
dinitrophenyl; DSPP, dentin sialophosphoprotein; ECE, endothelin-converting enzyme; EDDnp, N-(2,4-dinitrophenyl)ethylenediamine; FGF-23, fibroblast
growth factor-23; IQFP, internally quenched fluorogenic peptide; LLC-PK1 cells, porcine renal epithelial proximal tubule cells; MALDI–TOF, matrix-assisted-
laser-desorption ionization–time-of-flight; MEPE, matrix extracellular phosphoglycoprotein; NEP, neprilysin; OPN, osteopontin; PHEX, phosphate-regulating
gene with homologies to endopeptidases on the X chromosome; PTHrP107−139, parathyroid hormone-related peptide residues 107–139; secPHEX, soluble
secreted PHEX; TIO, tumour-induced osteomalacia; XLH, X-linked hypophosphataemia in humans.
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the involvement of NEP, ECE-1 and ECE-2 in regulating the
amount and hence activity of several bioactive peptides [15,16].
Sequence similarity of PHEX to other members of M13 family
suggests a similar role for PHEX. The demonstration that
a purified recombinant soluble and secreted form of PHEX
can hydrolyse parathyroid hormone-related peptide residues
(PTHrP107−139) is consistent with this hypothesis [17]. However,
the physiological relevance of PTHrP107−139 as a PHEX substrate
and its role in the pathogenesis of XLH are still unknown.
The major sites of PHEX expression are bone [3,18–22]
and teeth [22], but PHEX mRNA was also detected in ovary
[23], fetal lung [3,24] and in the parathyroid gland [25]. PHEX
expression is notably absent from kidney [3], suggesting that
it may regulate renal phosphate reabsorption by controlling the
activity of a circulating factor. Consistent with this hypothesis was
the demonstration that inhibition of Na+-dependent phosphate
transport in cultured renal cells can be achieved by a factor in
conditioned medium from cultured osteoblasts derived from Hyp
mice [26,27].
Phosphaturic activity(ies) have also been found in tumours from
patients with tumour-induced osteomalacia (TIO; also known
as oncogenic hypophosphataemic osteomalacia), an acquired
renal phosphate wasting disorder with the phenotypic features of
XLH [2]. The term ‘phosphatonin’ was designated to depict the
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phosphaturic tumours factor(s) [28], and although the exact nature
of phosphatonin remains to be determined, several candidates
have been proposed (for review, see [29]). It has been shown
that mutations in the FGF23 gene that encodes a novel growth
factor, fibroblast growth factor-23 (FGF-23) is responsible for
autosomal dominant hypophosphatemic rickets (ADHR), an
inherited disorder that resembles XLH and TIO [30]. Moreover,
it was demonstrated that over-expression of FGF-23 in animal
models elicits renal phosphate wasting, a reduction in serum
phosphate levels and osteomalacia [31]. Of interest was the finding
that FGF-23 is over-expressed in tumours from patients with TIO
[32]. In addition to FGF-23, other proteins such as Frizzled-related
protein 4 [32] and matrix extracellular phosphoglycoprotein
(MEPE) [33] are over-expressed in TIO tumours. However, the
phosphaturic activity of Frizzled-related protein-4 and MEPE in
animal models remains to be determined.
To better understand the relationship between PHEX and
phosphatonin, and to clarify conflicting data in the literature
about the hydrolytic activity of PHEX [17,20,34,35], we have
designed experiments to determine its substrate specificity using
internally quenched fluorogenic peptides (IQFPs) containing the
groups o-aminobenzoic acid (Abz), as the fluorescent donor,
and N-(2,4-dinitrophenyl)ethylenediamine (EDDnp) attached to
a glutamine residue or 2,4-dinitrophenyl (Dnp) attached to the ε-
amino group of lysine, as the fluorescent acceptor. Our results
indicate that PHEX has a strong requirement for an acidic
amino acid residue in the P′1 position of its substrates, and
that the enzyme prefers substrates with free C-terminal groups.
Furthermore, we demonstrated that several peptides derived from
biologically relevant proteins, such as FGF-23 and MEPE, are
PHEX substrates.
EXPERIMENTAL
Expression and purification of recombinant PHEX
The human recombinant soluble secreted form of PHEX
(secPHEX) was obtained as described previously [17]. The con-
centration of purified secPHEX was determined using the
Bradford method (DC protein assay kit; Bio-Rad, Mississauga,
Canada). Membrane-bound recombinant human PHEX was
expressed in porcine renal epithelial proximal tubule (LLC-PK1)
cells [17], and membranes were prepared essentially as described
by Guo et al. [34]. Briefly, transfected cells resuspended in lysis
buffer (150 mM NaCl/20 mM Tris/HCl, pH 7.6) were disrupted
by sonication. Cell debris was removed by centrifugation at 300 g
for 15 min at 4 ◦C. Membranes were collected by centrifugation
at 30 000 g for 50 min and solubilized for 2 h with 1% n-
dodecyl-β-D-maltoside in lysis buffer. Insoluble material was
pelleted by centrifugation at 10 000 g for 15 min, and protein
concentrations of the supernatant were determined using the
Bradford method (DC protein assay kit). PHEX amounts were
evaluated by immunoblotting as described previously [17].
NEP expression and purification were as described previously
[36].
N-terminal sequence determination
Purified secPHEX was analysed by SDS/PAGE on a 10.0% gel
[37]. Proteins were transferred to a PVDF membrane (Immobilon
O, Millipore), stained with Coomassie Blue, destained and washed
extensively with distilled water. The bands were excised and the
N-terminal sequence determined in a PPSQ-23 protein sequencer
(Shimadzu, Tokyo, Japan).
Synthesis of peptide libraries
Positional scanning IQFP combinatorial libraries were syn-
thesized as described previously [38,39], with the exception
that Abz/Dnp was used as fluorescence donor–acceptor pair.
For preliminary experiments we prepared a library with
the general structure Abz-GXXZXK(Dnp)-OH, where the Z
position was successively filled with one of 19 amino acids
(cysteine was omitted to avoid dimerization) and X contained
randomly incorporated residues. To ensure equal coupling of the
randomized residues, a balanced mixture of 19 amino acids was
used following the optimum composition described previously
[40]. Three other libraries were prepared with structures
Abz-GXXDZK(Dnp)-OH, Abz-GXZDXK(Dnp)-OH and Abz-
GZXDXK(Dnp)-OH, in which the P′1 position was pre-fixed as
aspartate, a second fixed position (Z = P′2, P1 and P2) included
19 naturally occurring amino acids and the other positions
were randomized (X = one of 17 amino acids; cysteine was
excluded to avoid dimerization; aspartate and glutamate were ex-
cluded of the mixture in order to force the hydrolysis only at the
fixed residue). Stock solutions were prepared in DMSO and
the concentrations were measured using the Dnp molar absorption
coefficient, ε365 = 17 300 M−1 · cm−1.
Synthesis and purification of peptides
IQFPs containing the group EDDnp attached to a glutamine
residue were synthesized by the solid-phase synthesis method
described previously [41] in a Shimadzu model PSSM-8
automated solid-phase peptide synthesizer. The IQFPs containing
the Dnp group incorporated to the ε-NH2 of a lysine residue
were synthesized by the solid-phase methodology, using fluoren-
9-ylmethoxycarbonyl-Lys(Dnp)-OH to introduce the quencher
group. All the peptides obtained were purified by semi-preparative
HPLC. The molecular mass and purity of synthesized peptides
were checked by amino acid analysis and by molecular mass
determination with matrix-assisted laser-desorption ionization–
time-of-flight MS (MALDI–TOF MS), using a TofSpec E
(Micromass, Manchester, U.K.). Stock solutions of Dnp or
EDDnp-peptides were prepared in DMSO and the concentrations
were measured using the Dnp molar absorption coefficient,
ε365 = 17 300 M−1 · cm−1.
Peptide library screen
Hydrolysis of peptides in the library was monitored under
optimum pH and salt concentrations previously established for
recombinant secPHEX using PTHrP107−139 as substrate [17],
namely 0.1 M Hepes, pH 6.5, containing 0.15 M NaCl. The
number of Zn2+ ions present in the enzyme after purification
has not been determined. However, in these conditions, addition
of 10−6 M ZnCl2 did not increase activity, suggesting that
the enzyme has retained its full complement of zinc during
purification. Enzymic activity in a final volume of 0.35 ml was
continuously followed at 37 ◦C in a Hitachi F-2000 fluorimeter
by measuring the fluorescence at λemission = 420 nm and λexcitation =
320 nm. The assays were performed at low substrate concent-
rations where the reactions followed first-order conditions
([S] Km), and the rate constant (kobs) was determined by the
non-linear regression data analysis Grafit program version 3.0
[42]. These determinations were done at two different substrate
concentrations and the apparent catalytic efficiencies, designated
∗kcat/Km, were obtained by dividing the kobs by the enzyme
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concentration. The error was less than 5% for any obtained
value.
Optimum pH determination
The pH dependence was studied using 0.2 µM Abz-GFSDYK
(Dnp)-OH over a pH range 3.5–8.5. The buffers used were as
follows: 0.01 M sodium acetate (3.5 < pH < 5.1), 0.01 M Bis/Tris
(5.1 < pH < 6.5), 0.01 M Hepes (6.5 < pH < 7.4) and 0.01 M
Tris/HCl (7.4 < pH < 8.4) containing 0.14 M NaCl. Enzymic
activity was followed at 37 ◦C using the continuous fluorimetric
assay. For each pH, the apparent second-order rate constant
(∗kcat/Km) was determined at low substrate concentrations
where the reactions followed first-order conditions ([S] 
Km).
NaCl influence on catalytic activity
The influence of salt on secPHEX catalytic activity was inves-
tigated using 0.2 µM Abz-GFSDYK(Dnp)-OH as substrate at
37 ◦C in 0.01 M Bis/Tris buffer, pH 5.5, over a NaCl range
0–500 mM. The increase in fluorescence was continuously
measured at 37 ◦C and the apparent second-order rate constant
(∗kcat/Km) for the different NaCl concentrations was calculated as
described above.
Determination of kinetic parameters for synthetic peptides derived
from the peptide libraries and from putative natural substrates
The hydrolysis of the IQFPs at 37 ◦C in 10 mM Bis/Tris
buffer, pH 5.5, (0.35 to 1.0 ml final volume) containing 150 mM
NaCl, was continuously followed measuring the fluorescence
at λemission = 420 nm and λexcitation = 320 nm in a Hitachi F-
2000 spectrofluorimeter. The cuvette containing the buffer and
the substrate was placed in a thermostatically controlled cell
compartment for 5 min before the addition of the enzyme, and the
increase in fluorescence with time was continuously recorded for
5–10 min. The enzyme concentration for initial rate determination
was chosen at a level intended to hydrolyse less than 5% of the
substrate present. The slope was converted into µmol of substrate
hydrolysed per min based on a calibration curve obtained from
complete hydrolysis of each peptide. The inner-filter effect was
corrected using an empirical equation as described previously
[43]. The kinetic parameters Km and kcat were calculated by the
non-linear regression data analysis Grafit program. The kcat/Km
values were calculated as the ratio of these two determined
parameters. The apparent second-order rate constant kcat/Km
(∗kcat/Km) was determined under pseudo-first-order conditions,
where [S] Km. These determinations were performed in two
different substrate concentrations and the errors were less than
5% for any obtained value.
Determination of secPHEX cleavage sites
To determine the position of cleavage in peptides of the
IQFPs combinatorial libraries, the products resulting from total
hydrolysis by secPHEX were submitted to N-terminal amino
acid sequencing in a PPSQ-23 protein sequencer (Shimadzu).
The scissile bonds in the IQFPs derived from PTHrP107−139,
FGF-23 and MEPE were determined by amino acid sequencing
and by MALDI-TOF MS (TofSpec-E) after isolation of the
fragments resulting from the hydrolysis by secPHEX by analytical
HPLC.
RESULTS
secPHEX specificity determined by peptide libraries
Positional scanning synthetic combinatorial libraries were used
to identify the P2 to P′2 substrate specificity of secPHEX. P2 to
P′2 are defined according to the nomenclature of Schechter
and Berger [44]. We found that secPHEX requires an acidic
residue in P′1 position, as demonstrated using the library with the
general sequence Abz-GXXZXK(Dnp), where only the peptides
Abz-GXXDXK(Dnp) and Abz-GXXEXK(Dnp) were hydrolysed
(Figure 1A). The products resulting from cleavage were submitted
to N-terminal amino acid sequencing, and the presence of an
aspartate or a glutamate as the first residue of the fragments
DXK(Dnp) and EXK(Dnp) respectively was confirmed. However,
a clear preference was observed for an aspartate residue in
this position, as substitution with a glutamate residue resulted
in almost 5-fold reduction on the catalytic efficiency (∗kcat/Km)
(Figure 1A).
Based on the results from the first library, three other
libraries with general structures Abz-GXXDZK(Dnp), Abz-
GXZDXK(Dnp) and Abz-GZXDXK(Dnp), in which P ′1 was
fixed as aspartate, were synthesized and tested with recombinant
secPHEX to determine the S′2, S1 and S2 specificities respectively.
We observed that the P ′2 position showed a moderate preference
for amino acids with aromatic side chains such as phenylalanine
and tyrosine, as well as for polar residues such as serine and
threonine (Figure 1B). In contrast, substrates containing leucine,
proline and glycine in this position were resistant to hydrolysis by
secPHEX. The S1 subsite accepted a broad range of amino acids,
although substrates containing isoleucine, valine and histidine
in this position were resistant to hydrolysis (Figure 1C). No
impeditive residues were detected in P2 position, since secPHEX
was able to hydrolyse all substrates of the Abz-GZXDXK(Dnp)
series. However, in this library, peptides containing the amino
acids arginine, lysine, asparagine and glutamine in P2 were the
least preferred substrates (Figure 1D).
A model peptide containing the most favourable amino acid
residue in each position screened by the libraries was next
synthesized. The resulting sequence, Abz-GFSDYK(Dnp)-OH,
was used to better characterize the enzyme and to establish the
optimum assay conditions for the kinetic studies.
pH activity profiles and NaCl dependence
The effect of pH on the hydrolysis of Abz-GFSDYK(Dnp)-
OH by secPHEX was determined over a pH range 3.5–8.5. A
bell-shaped curve was obtained, with maximum kcat/Km values
occurring around pH5.5 (Figure 2). A significant influence of
NaCl concentration on the catalytic efficiency of recombinant
secPHEX was also detected, as shown in the inset of Figure 2.
kcat/Km values in presence of 10 mM Bis/Tris, containing 150 mM
NaCl, pH 5.5, were more than 2-fold lower than in the absence of
added salt. However, the presence of the salt is essential for the
Km and kcat determinations, since in absence of NaCl the enzyme
is gradually inactivated (results not shown).
Effects of substrate C-terminus modification
We next examined the effect of amidating the C-terminus of
substrates on cleavage efficiency by secPHEX. Two substrates,
Abz-GFSDYK(Dnp)-OH and Abz-GFSEYK(Dnp)-OH (peptides
I and IV, Table 1), and their C-terminus amidated analogues
(peptides II and V, Table 1), were used to compare the activity of
secPHEX. The kinetic parameters presented in Table 1 show that
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Figure 1 Scanning for amino acid residues preferred by secPHEX in substrate subsites P2 to P′2
Positional scanning fluorimetric combinatorial libraries with general sequences Abz-GXXZXK(Dnp)-OH (A), Abz-GXXDZK(Dnp)-OH (B), Abz-GXZDXK(Dnp)-OH (C) and Abz-GZXDXK(Dnp)-OH
(D) were incubated with secPHEX (0.2–0.45 µM) in 0.1 M Hepes/150 mM NaCl, pH 6.5, at 37 ◦C. The assays were performed at a low substrate concentration where the reactions followed
first-order conditions ([S]  K m). The y-axis represents the apparent catalytic efficiency values (*k cat/K m) obtained as described in the Experimental section. The x-axis shows the specific amino
acid represented by the one-letter code. The errors were less than 5 % for any obtained value.
Figure 2 pH and NaCl (inset) dependence of Abz-GFSDYK(Dnp)-OH
hydrolysis by secPHEX
The pH activity profile for the hydrolysis of Abz-GFSDYK(Dnp)-OH by PHEX in presence of
different buffers and pH conditions is as described in the Experimental section. Inset: the effect
of NaCl is shown; Abz-GFSDYK(Dnp)-OH was incubated with secPHEX in 0.01 M Bis/Tris buffer,
pH 5.5, with NaCl (0–0.5 M).
Table 1 Kinetic constants for the hydrolysis by PHEX of IQFPs designed by
screening combinatorial libraries
The assays were performed at 37 ◦C in 10 mM Bis/Tris containing 150 mM NaCl, pH 5.5.
Measurements were made as described in the Experimental section. Cleavage sites are indicated
as arrows ( ↓ ). The S.D. of the kinetic constants were less than 5 %.
k cat/K m
Number Peptides K m (µM) k cat (s−1) (mM−1 · s−1)
I Abz-GFS ↓ DYK(Dnp)-OH 3 0.5 167
II Abz-GFS ↓ DYK(Dnp)-NH2 53 1.3 25
III Abz-GFS ↓ DYQ-EDDnp 13 0.6 46
IV Abz-GFS ↓ EYK(Dnp)-OH 9*
V Abz-GFSEYK(Dnp)-NH2 resistant
* k cat/K m values were determined under pseudo-first-order conditions.
the model peptide Abz-GFSDYK(Dnp)-OH (peptide I, Table 1)
was the best substrate of the series (kcat/Km = 167 mM−1 · s−1),
due to its high affinity for PHEX. On the other hand, its amidated
analogue Abz-GFSDYK(Dnp)-NH2 (peptide II, Table 1) was
hydrolysed by the enzyme with a high kcat value, but with a
7-fold decrease in catalytic efficiency due to its low affinity
for the enzyme. As expected from the results of the peptide
library studies described above, secPHEX catalytic efficiency
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Table 2 Kinetic constants for hydrolysis by PHEX of IQFPs based on
PTHrP107−139 sequence
Conditions of hydrolysis are as described in Table 1. Cleavage sites are indicated by arrows
( ↓ ). The S.D. of the kinetic constants were less than 5 %.
k cat/K m
Number Peptides* K m (µM) k cat (s−1) (mM−1 · s−1)
I Abz- D124-HLS ↓ DTSTQ-EDDnp 1.3 0.1 77
II Abz-L134-EL ↓ DSRQ-EDDnp 0.9 0.05 55
III Abz-A110-WL ↓ DSGVQ-EDDnp 1.5 0.04 27
* The numbers in the peptides sequences identify the position of the residues in PTHrP107−139.
was lower with Abz-GFSEYK(Dnp)-OH (peptide IV, Table 1),
containing glutamate in P′1 and a free carboxy group, than that
observed with the Asp-containing analogue (peptide I, Table 1).
Abz-GFSEYK(Dnp)-NH2 (peptide V, Table 1) was resistant to
hydrolysis, confirming that substrates with blocked C-terminal
groups are less susceptible to hydrolysis by secPHEX. Replacing
K(Dnp) by Q-EDDnp at the C-terminal end of the model
peptide resulted in an decrease of the kcat/Km value for peptide
Abz-GFSDYQ-EDDnp (compare peptides I and III, Table 1).
Q-EDDnp is present in peptides prepared by the solid-phase
synthesis method.
Hydrolysis of peptides based on PTHrP107−139
The secPHEX was reported to cleave PTHrP107−139 at three
positions [17]. To determine cleavage efficiency of this sub-
strate, peptides with sequences encompassing the identified
hydrolysed peptide bonds were synthesized and incubated with
secPHEX. The enzyme had a high affinity for these peptides (low
Km values), but low kcat values (Table 2). Despite the low catalytic
constant, peptide Abz-D124-HLSDTSTQ-EDDnp (peptide I,
Table 2) was hydrolysed with kcat/Km value of 77 mM−1 · s−1,
and was a good substrate for secPHEX. In all cases, hydrolysis of
the substrates occurred at N-terminus of an aspartate residue.
Hydrolysis of peptides based on human FGF-23 sequence
FGF-23 has been proposed as a PHEX substrate [45]. Using
the information gathered from the combinatorial libraries about
the most favourable amino acids in the P2 to P′2 positions, the
FGF-23 sequence [31] was scanned for putative cleavage sites
and IQFPs analogues containing aspartate or glutamate were
synthesized. Cysteine residues found in human FGF-23 sequence
were substituted with methionine to avoid synthesis problems.
In spite of the presence of more than one putative scissile bond
in some peptides, all substrates of this series were hydrolysed
at a single cleavage site at the N-terminus of aspartate residues,
as determined by N-terminal sequencing. The kinetic parameters
presented in Table 3 reveal that Abz-R175-RHTRSAEDDSERQ-
EDDnp and Abz-R175-RHTQSAEDDSERQ-EDDnp (peptides III
and IV), the longest substrates tested, showed the highest kcat/Km
values of this series, due to their high affinities for the enzyme. The
peptide Abz-L94-MMDFRGQ-EDDnp (peptide I, Table 3) had a
low affinity for the enzyme, but the highest kcat value. Peptides
Abz-S212-AEDNSPQ-EDDnp and Abz-R76-SEDAGFQ-EDDnp
(peptides V and VI, Table 3) presented poor catalytic efficiencies,
and Abz-N122-GYDVYHQ-EDDnp (peptide II, Table 3) was the
poorest substrate of this series. The Arg179 to Gln mutation in
FGF-23 was shown to result in ADHR in humans [30]. To test
Table 3 Kinetic constants for hydrolysis by PHEX of IQFPs based on FGF-23
sequence
Conditions of hydrolysis are as described in Table 1. Cleavage sites are indicated as arrows
( ↓ ). The S.D. of the kinetic constants were less than 5 %.
k cat/K m
Number Peptides* K m (µM) k cat (s−1) (mM−1 · s−1)
I Abz- L94-MM ↓ DFRGQ-EDDnp 17 0.8 47
II Abz- N122-GY ↓ DVYHQ-EDDnp 9 0.01 1.1
III Abz-R175-RHTRSAED ↓ DSERQ-EDDnp 3 0.2 67
IV Abz-R175-RHTQSAED ↓ DSERQ-EDDnp 1.7 0.15 88
V Abz- S212-AE ↓ DNSPQ-EDDnp 22 0.3 14
VI Abz- R76-SE ↓ DAGFQ-EDDnp 4 0.06 15
* The numbers in the peptide sequences identify the position of the residues as in FGF-23.
Table 4 Kinetic constants for hydrolysis by PHEX of IQFPs based on MEPE
sequence
Conditions of hydrolysis are as described in Table 1. Cleavage sites are indicated as arrows
( ↓ ). The standard deviations of the kinetic constants were less than 5 %.
k cat/K m
Number Peptides* K m (µM) k cat (s−1) (mM−1 · s−1)
I Abz-GP197-QR ↓ DSQAQ-EDDnp 47 0.2 4
II Abz-I232-PS ↓ DFEGQ-EDDnp 80†
III Abz-T294-HL ↓ DTKKQ-EDDnp 15 0.02 1.3
IV Abz-G337-SN ↓ DIMGQ-EDDnp 13 0.01 0.8
V Abz-G386-SS ↓ DAAEQ-EDDnp 2.4 0.3 125
VI Abz-R441-GL ↓ DNEIQ-EDDnp 7 0.03 4
VII Abz-N449-EM ↓ DSFNQ-EDDnp 37 0.3 8
VIII Abz-R506-RD ↓ DSSEQ-EDDnp 5 0.5 100
IX Abz-S513-S ↓ DSGSQ-EDDnp 32 0.2 6
* The numbers in the peptide sequences identify the residues as in MEPE.
† k cat/K m value determined under pseudo-first-order conditions.
whether this mutation interferes with secPHEX cleavage of FGF-
23, peptide Abz-R175-RHTQSAEDDSERQ-EDDnp (peptide IV,
Table 3) was synthesized and incubated with secPHEX. The
mutation did not alter secPHEX cleavage of the peptide (compare
peptides III and IV, Table 3).
Hydrolysis of peptides based on human MEPE sequence
As was done for FGF-23, the human MEPE sequence [33] was
mapped, and IQFPs derivatives containing aspartate or glutamate
were synthesized and tested as secPHEX substrates. Again, all
peptides were hydrolysed at a single cleavage site in the N-
terminus of an aspartate residue as presented in Table 4. The
majority of the substrates of this series were hydrolysed with
poor catalytic efficiency due to low kcat and high Km values.
However, peptides Abz-G386-SSDAAEQ-EDDnp and Abz-R506-
RDDSSEQ-EDDnp (peptides V and VIII, Table 4) showed the
best kcat/Km values, which was due mainly to their high affinity
for the enzyme.
Comparison of membrane-bound PHEX and secPHEX activity
It can be argued that engineering a soluble form of PHEX may
change the specificity of the enzyme. To rule out this possibility,
we first performed N-terminal sequencing of purified secPHEX
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Figure 3 Hydrolysis of Abz-GFSDYK(Dnp)-OH by secPHEX and membrane-
bound PHEX
Abz-GFSDYK(Dnp)-OH at a concentration of 10 µM was incubated at 37 ◦C in 0.01 M Bis/Tris
buffer, pH 5.5, with 150 mM NaCl, containing 2.1 µg of total proteins from membranes extracted
from LLC-PK1 cells transfected with vector alone (), 2.1 µg of total proteins from membranes
extracted from LLC-PK1 cells transfected with the membrane-bound form of human PHEX ()
or 2.1 µg of total proteins from membranes extracted from LLC-PK1 cells transfected with vector
alone to which 500 ng of purified secPHEX was added (). Fluorescence was monitored every
4 min for a period of 30 min. Amounts of secPHEX (sPHEX) or membrane-bound PHEX (mPHEX)
in the enzymic reactions were evaluated by immunoblotting (inset). Mock, cells transfected with
vector alone. AFU, arbitrary fluorescence units.
to determine the number of amino acid residues lacking in the
enzyme ectodomain. Residue Ser46 (of human PHEX sequence as
reported in [3]) was found as the first secPHEX residue.
LLC-PK1 cells were then transfected with membrane-bound
PHEX cDNA, and PHEX activity in the membrane fraction
was compared with secPHEX, using Abz-GFSDYK(Dnp)-OH as
substrate. To obtain a better comparison between secPHEX and
membrane-bound PHEX in this series of experiments, secPHEX
was added to membranes purified from cells transfected with
vector alone. When similar amounts of secPHEX and membrane-
bound PHEX, as evaluated by immunoblotting (Figure 3, inset),
were added to the enzymic assay, degradation of the sub-
strate was observed (Figure 3). No substrate hydrolysis was
evident with membranes from cells transfected with vector alone.
A higher rate of hydrolysis was observed with secPHEX, which
also showed a slightly lower Km value (5 × 10−6 M and 10 ×
10−6 M, for secPHEX and membrane-bound PHEX respectively).
N-terminal sequencing of the hydrolysis products showed that
both enzymes cleaved substrate Abz-GFSDYK(Dnp)-OH at the
N-terminus of the aspartate residue.
We also compared the activities of membrane-bound PHEX
and secPHEX with the NEP-specific substrate Abz-rRL-
EDDnp [46]. Neither enzyme hydrolysed this substrate
(Figure 4, upper panel). In addition, the NEP-specific inhibitor
thiorphan did not prevent cleavage of substrate Abz-GFSDYK
(Dnp)-OH by membrane-bound or secPHEX (Figure 4, lower
panel). In contrast, NEP activity was completely inhibited by the
same concentration of thiorphan (Figure 4, upper panel). These re-
sults demonstrated that engineering human PHEX into a soluble
enzyme did not affect its activity and specificity, and that PHEX
does not display a NEP-like activity.
DISCUSSION
Data collected from the Hyp mouse model and human XLH
patients [2] suggest that PHEX plays an important role in the
control of phosphate homoeostasis and skeletal mineralization.
Figure 4 Activity of PHEX in the presence of NEP-specific substrate and
inhibitor
NEP, secPHEX (sPHEX) and membrane-bound PHEX (mPHEX) activities were measured after
30 min of incubation in presence of either 10 µM Abz-rRL-EDDnp (upper panel) or 10 µM Abz-
GFSDYK(Dnp)-OH (lower panel). Fluorescence detection (AFU, arbitrary fluorescence units) at
λemission = 420 nm and λexcitation = 320 nm was determined as described in the Experimental
section. When present, thiorphan, a NEP-specific inhibitor, was at a concentration of 10−6 M.
Results are the means +− S.D. for three different experiments.
However, the mechanism(s) by which PHEX regulates these
physiological processes is still unknown. Homologies between
PHEX and endopeptidases of the M13 family suggest that PHEX
may hydrolyse biologically active peptides and in this way control
their activity. Although several candidates, such as parathyroid
hormone [20], PTHrP107−139 [17], FGF-23 [45] and MEPE
[47], have been proposed, no physiologically relevant PHEX
substrate has yet been identified, and the substrate specificity of
the enzyme is not known. In the present study, we used a soluble
secreted form of recombinant human PHEX (secPHEX) that can
be easily purified to probe the enzyme substrate specificity. We
showed that the secPHEX protein lacks 45 amino acid residues
at the N-terminal, starting at residue Ser46 of the native PHEX
sequence. Considering that PHEX has a 20-amino-acid-long
cytoplasmic domain (from Met1 to Arg20) and a transmembrane
segment of at least 20 residues, our results indicate that secPHEX
is lacking, at the most, five residues from its extracellular
domain. The three-dimensional structure of NEP indicated that
this segment of the protein probably forms the stalk that maintains
the enzyme away from the surface of the cell, and does not
contain amino acid residues important for substrate binding or
catalytic activity [48]. It is thus unlikely that the absence of
these five residues would change secPHEX specificity. This
hypothesis was confirmed by our demonstration that both the
recombinant membrane-bound and soluble secreted forms of
the enzyme cleaved the substrate Abz-GFSDYK(Dnp)-OH
at the same position and that both forms of the enzyme have
a similar affinity for the substrate.
The development of positional scanning combinatorial
fluorogenic peptide libraries allowed us to test and evaluate
c© 2003 Biochemical Society
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PHEX substrate specificity in vitro. The results clearly show an
unequivocal preference of PHEX for cleavage at the N-terminus
of acidic amino acid residues (aspartate or glutamate), with a
strong bias for aspartate residues. These results are in accordance
with the previously reported observation that PHEX hydrolysed
PTHrP107−139 at three positions all located at the N-terminus of
an aspartate residues, and consistent with our observation that a
positively charged arginyl side chain is possibly present in the
PHEX S′1 pocket and could form an ionic bond with the aspartate
side chain of the substrate [17]. Indeed, whereas the NEP three-
dimensional structure showed that the S′1 pocket is lined with
seven hydrophobic amino acids residues, namely Phe106, Ile558,
Phe563, Met579, Val580, Val692 and Trp693, sequence comparisons
have identified Tyr109, Glu554, Phe559, Val576, Ile577, Val691 and
Arg692 as the homologous residues in PHEX [17]. It is interesting
to underline that neither secPHEX nor membrane-bound PHEX
could hydrolyse the NEP substrate Abz-rRL-EDDnp, and that
neither enzyme was inhibited by the NEP inhibitor thiorphan.
These results support our previous observation [17] that PHEX
could not cleave several well-known NEP substrates, including
enkephalins and substance P. Thus our work clearly shows that
PHEX and NEP have different substrate specificities, and is not
in agreement with reports that PHEX is able to hydrolyse NEP
substrates, such as Leu-enkephalin [34] and the chromogenic
peptide benzyloxycarbonyl-Ala-Ala-Leu-p-nitroanilide [35], as
these peptides do not have acidic residues in their amino acid
sequences.
Libraries with a fixed asparate residue in the P′1 position were
next synthesized in order to define extended substrate specificity.
We found that the S′2, S1 and S2 subsites are much less restrictive
than the S′1 subsite. However, we observed that specific residues
in the P′2 (leucine, proline and glycine) and P1 (isoleucine, valine
and histidine) positions precluded hydrolysis by secPHEX. From
these results, a model peptide with the most favourable amino
acid residue in each position was synthesized. This peptide, Abz-
GFSDYK(Dnp)-OH, was the best PHEX substrate among all the
peptides tested in the present study (kcat/Km = 167 mM−1 · s−1),
and was used to determine the optimum conditions for a PHEX
enzymic assay.
We also showed that, similar to NEP, PHEX prefers sub-
strates with a free C-terminus. Amidating the C-terminus of
substrate Abz-GFSDYK(Dnp)-OH resulted in an almost 7-fold
decrease in PHEX catalytic efficiency. Similar results were also
obtained with substrate Abz-GFSEYK(Dnp)-OH and its amidated
counterpart. In NEP, Arg102 has been proposed to form an ionic
interaction with the free C-terminus of some substrates [49]. By
sequence homology, Lipman et al. [20] could not identify an
equivalent residue in PHEX. Our results suggest that the residue
responsible for the ionic interaction with the free C-terminus
of substrates might also be present in the active site of PHEX.
Clearly, a more systematic study, using substrates modified at
their C-terminus and PHEX proteins in which critical amino-acid
substitutions have been introduced by site-directed mutagenesis
of the cDNA, is necessary to identify this residue.
Based on biochemical and genetic evidence, several proteins/
peptides have been proposed as PHEX substrates. These include
PTHrP107−139 [17], FGF-23 [45] and MEPE [47]. To determine
whether PHEX cleavage sites were present, the sequences of
these proteins/peptides were scanned for regions containing
aspartate or glutamate residues in a favourable context for
PHEX cleavage, as identified above, and IQFPs derivatives
were synthesized accordingly. Our results show that these three
proteins/peptides contain several PHEX cleavage sites that are
hydrolysed more or less efficiently by the enzyme. In particular,
the enzyme had a high affinity for the FGF-23-derived substrate
Figure 5 Representation of the positions of the synthetic peptides in MEPE
and FGF-23 structure
(A) MEPE structure: numbers correspond to the first and last amino acid residues of MEPE,
including the signal sequence. The black box represents MEPE sequence homologous to
sequences found in DMP1, DSPP and OPN. The boxes under MEPE structure correspond
to the position in MEPE sequence of the peptides presented in Table 4. Numbering is as in
Table 4. (B) FGF-23 structure: numbers correspond to the first and last amino acid residues
of FGF-23, including the signal sequence. R176HTR179 (Arg176-His-Thr-Arg179) indicate the
position of the convertase cleavage site found in FGF-23 sequence. The boxes under FGF-23
structure correspond to the position in FGF-23 sequence of the peptides presented in Table 3.
Numbering is as in Table 3.
Abz-R175-RHTRSAEDDSERQ-EDDnp (peptide III, Table 3) and
for MEPE-derived peptide Abz-R506-RDDSSEQ-EDDnp (peptide
VIII, Table 4), and in both cases cleaved substrates between
two aspartate residues. The latter peptide is located in the C-
terminal domain of MEPE (see Figure 5A), a region with strong
homologies with several bone and teeth proteins including dentin
matrix protein 1 (DMP1), dentin sialophosphoprotein (DSPP)
and osteopontin (OPN) [33]. These homologies suggest that
DMP1, DSPP and OPN are also putative PHEX substrates. This
region also contains a protein kinase CK2 (casein kinase II)
phosphorylation site that suggests a regulatory role.
Of particular interest is the peptide Abz-R175-
RHTRSAEDDSERQ-EDDnp. This sequence contains FGF-23
furin cleavage site that is mutated in ADHR (Arg176 and Arg179;
see Figure 5B) [30]. Bowe et al. [45] have observed that in
vitro-translated wild-type FGF-23 was hydrolysed by in vitro-
translated PHEX, whereas mutant FGF-23 with a Arg179→Gln
substitution (R179Q) was resistant to hydrolysis by the enzyme,
suggesting that the mutation could interfere with PHEX cleavage
of this protein. However, we could not reproduce this result
using short peptides. The FGF-23-derived peptide substrate
carrying the R179Q mutation was cleaved as efficiently by
PHEX as the wild-type FGF-23-derived peptide. This result
is consistent with results generated from the combinatorial
libraries, demonstrating that only subsites close to the cleavage
site have an impeditive influence. Guo et al. [34] have reported
that FGF-23 peptide P172-IPRRHTRSAEDDSE was resistant to
hydrolysis by PHEX. This peptide has the PHEX cleavage site
identified in Abz-R175-RHTRSAEDDSERQ-EDDnp (in between
the two aspartate residues), and incubation with PHEX should
release the tripeptide Asp-Ser-Glu. It is, however, possible that
the release of this very hydrophilic tripeptide was missed in the
HPLC system used to monitor PHEX activity.
The discrepancy in the results raises the question of whether the
PHEX substrate specificity observed with small synthetic peptides
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can be extended to the hydrolysis of large natural proteins. The
crystal structure of NEP indicates that the presence of a two-
domain structure restricts the access of the active site to small
peptides [48]. Although the three-dimensional structure of PHEX
is still not known, its homology with NEP would suggest that both
enzymes function as oligopeptidases, as these proteins present
a common origin and a similar fold [48]. If this hypothesis is
correct, full-length FGF-23 and MEPE could not be cleaved by
PHEX. However, it has been shown that FGF-23 is processed
to smaller fragments during its biosynthesis, and that mutations
in FGF-23 resulting in ADHR in human patients precluded this
processing [50]. Similarly, Argiro et al. [47] postulated that
MEPE is first cleaved by an uncharacterized metallopeptidase,
and that one of the fragments generated is the phosphaturic
factor processed by PHEX. In addition, Quarles and Drezner
[51] have reported phosphaturic activity of truncated MEPE
fragments. Thus, despite functioning as an oligopeptidase, PHEX
may be involved in controlling the activity of FGF-23 and/or
MEPE by cleaving their processed peptide products. Further
studies are necessary to characterize the size selectivity of PHEX
substrates.
In conclusion, we have developed an enzymic assay for PHEX
using IQFPs that has the advantage of high sensitivity and allows
the possibility to monitor the reaction on a continuous basis.
This enzymic assay can be helpful to develop inhibitors, better
characterize the enzyme and understand its physiological role.
We have also provided evidence that peptides derived from
physiologically relevant proteins, such as FGF-23 and MEPE,
are PHEX substrates.
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